Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 3/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
| ▸ | ACE | P12821 | 1/20 | 0.34 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL623843 | 0.89 | DPP4 (0.39) | DPP4DPP8CYP2D6MTNR1BKDM4E | |
| SCHEMBL622279 | 0.85 | DPP4 (0.43) | DPP4DPP8CYP2D6MTNR1BKDM4E | |
| SCHEMBL30997677 | 0.82 | NR1H2 (0.45) | DPP4DPP8MTNR1BMTNR1ADRD2 | |
| SCHEMBL20768178 | 0.82 | DPP4 (0.39) | DPP4DPP8CYP2D6KMT2AMEN1 | |
| SCHEMBL31020103 | 0.82 | DPP4 (0.39) | DPP4DPP8CYP2D6KMT2AMEN1 | |
| SCHEMBL14575206 | 0.82 | NR1H2 (0.45) | DPP4DPP8MTNR1BMTNR1ADRD2 | |
| SCHEMBL31020007 | 0.78 | MTNR1B (0.48) | CYP2D6MTNR1BACE | |
| SCHEMBL22366344 | 0.78 | MTNR1B (0.48) | CYP2D6MTNR1BACE | |
| SCHEMBL3607650 | 0.75 | GHSR (0.44) | ACE | |
| SCHEMBL4082356 | 0.75 | DPP4 (0.42) | DPP4DPP8MTNR1BMTNR1ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150158842-A1 | PHENALKYLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-06-11 | — | — | US | disclosed |
| US-9045459-B2 | Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-06-02 | — | — | US | disclosed |
| US-20120088790-A1 | PHENALKYLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT GMBH & CO. KG (DE) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150158842-A1 | PHENALKYLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | KCNT1, CEPT1, PIGT | DPP4 525/4885DPP8 776/4885CYP2D6 305/4885 |
| US-20120088790-A1 | PHENALKYLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | KCNT1, CEPT1, PIGT | DPP4 525/4885DPP8 776/4885CYP2D6 305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.